Edwards Lifesciences Corporation (NYSE:EW) shares opened significantly higher on Friday following a quarterly earnings report that exceeded analyst expectations. The stock gapped up from a previous close of $83.82 to an opening price of $88.00, trading at $86.84 with a volume of 1.41 million shares....
Bullish Signals
Beat EPS estimates by $0.04 at $0.78 per share.
Revenue of $1.74 billion exceeded analyst expectations.
Year-over-year revenue growth reached 13.6%.
Raised guidance for Q3 and FY 2026 EPS.
Institutional investors increased stakes significantly, including UBS.
Debt-to-equity ratio remains extremely low at 0.06.
Strong liquidity with current ratio of 4.42.
Bearish Signals
Senior VP Andrew M. Dahl sold 568 shares ($48,893.44).
Edwards Lifesciences Corp. reported first-quarter results that exceeded analyst expectations, driving its shares up 4.7% to $83.49 in after-hours trading with a market capitalization of approximately $46 billion. The Irvine-based medical device company posted revenue of $1.65 billion, surpassing the $1.6 billion forecast, while earnings...
Bullish Signals
Shares rose 4.7% after Q1 revenue beat expectations.
Edwards Lifesciences Corporation (NYSE:EW) saw Vice President Donald Bobo, Jr. sell 48,900 shares on November 9th under a pre-arranged Rule 10b5-1 trading plan. The transaction averaged $103.05 per share, totaling approximately $5.04 million, reducing his personal holding to roughly 22,798 shares. This insider sale represents...
Bullish Signals
EPS beat estimates at $0.80 vs $0.74 consensus.
Bearish Signals
VP Bobo sold shares worth $5.04M, reducing stake by 68.2%.
Institutional investors have significantly increased their stakes in Edwards Lifesciences Corporation (NYSE:EW) during the first quarter of 2026. AIA Group Ltd raised its position by 7.9%, adding over 10,000 shares worth nearly $11 million. Major additions also came from Norges Bank, UBS Asset Management, Viking...
Truist Financial has raised its price target for Edwards Lifesciences (NYSE:EW) from $90.00 to $95.00, citing potential upside of 10.82% from current levels, though maintaining a 'hold' rating. This move aligns with broader analyst sentiment, as the consensus rating remains 'Moderate Buy' with an average...
Bullish Signals
Analysts see 10.82% upside to Truist's $95.00 price target.
Company beat EPS estimates, reporting $0.78 versus $0.73 consensus.
Revenue grew 16.7% YoY to $1.65 billion, beating expectations.
Consensus rating is Moderate Buy with average target of $98.95.
Major banks raised targets to $110.00 and $105.00.
Bearish Signals
VP Bobo sold 23,145 shares ($2M), dropping ownership 19.01%.
SVP Dahl sold 568 shares ($49K) to reduce holdings.
ABN AMRO Bank N.V. significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 124.5% in the first quarter, purchasing an additional 220,969 shares. This brings ABN AMRO's total holding to 398,425 shares, valued at approximately $32.26 million as of their latest SEC filing. Other...
Bullish Signals
ABN AMRO increased holdings by 124.5% to 398,425 shares valued at $32.26 million.
State State Corp owns 25,991,524 shares worth $2.22 billion after a 1.5% increase.
Edwards Lifesciences Q1 EPS of $0.78 beat the consensus estimate of $0.73.
Revenue reached $1.65 billion, growing 16.7% year-over-year and exceeding estimates.
Net margin is 17.39% with a return on equity of 15.19%.
Bearish Signals
Insiders sold 81,038 shares worth $6.68 million in 90 days.
VP Lippis sold 620 shares for $50,306.80 on May 18th.
CFO Ullem sold 13,000 shares for $1.04M on April 9th.
Edwards Lifesciences Corporation (EW) reported first-quarter 2026 adjusted earnings per share (EPS) of 78 cents, surpassing the Zacks Consensus Estimate by 16.4% and representing a 21.9% year-over-year increase. While sales totaled $1.65 billion, matching the consensus estimate, they grew 17% year over year. One-time adjustments...
Bullish Signals
Edwards Lifesciences beat Q1 earnings estimates with adjusted EPS of 78 cents, exceeding the consensus by 16.4% and marking a 21.9% year-over-year increase.
Sales reached $1.65 billion, aligning perfectly with analyst expectations while growing 17% year over year to demonstrate strong demand.
The TAVR segment drove significant growth with global sales up 14.4% to $1.20 billion, fueled by increased adoption of the SAPIEN 3 Ultra RESILIA platform.
Transcatheter Mitral and Tricuspid Therapies saw explosive growth, with sales surging 51.9% year over year as clinicians adopt PASCAL and EVOQUE devices.
Global Surgical sales grew 10.1% to $276.2 million, driven by the sustained market uptake of RESILIA therapies which offer extended durability.
Operating income expanded 28.1% year over year to $500.5 million, reflecting an operating margin expansion of 269 basis points to 30.4%.
Management raised its full-year 2026 sales growth guidance range from 8-10% to 9-11%, signaling confidence in continued market momentum.
The company strengthened its balance sheet with $2.40 billion in cash and cash equivalents while maintaining manageable debt levels around $600 million.
Bearish Signals
Gross profit margins contracted by 64 basis points year over year to 78%, primarily due to a significant 20.2% increase in the cost of sales.
Cash and cash equivalents decreased from $3.00 billion in the fourth quarter of 2025 to $2.40 billion at the end of Q1 2026, indicating a drawdown in liquidity despite strong revenue growth.
The company's Q2 guidance for adjusted EPS is lower than Q1 results ($0.70-$0.76 vs the implied prior quarter strength), suggesting a potential peak in profitability this year.
Edwards Lifesciences stock slipped approximately 2.8% to trade around $84.31 on September 11, 2026, following a Medicare coverage update for transcatheter aortic valve replacement (TAVR) procedures. Despite the immediate price dip, analysts from major firms like BTIG and Citi reaffirmed their Buy ratings with price...
Bullish Signals
Full-year 2026 guidance reaffirmed with 10-11% sales growth.
Quarterly EPS beat consensus at $0.78 vs $0.74.
Revenue hit $1.74B, up 13.6% year over year.
Analysts maintain Buy ratings with ~$101 average target.
Bearish Signals
Shares slipped 2.8% intraday to $84.31 on Medicare TAVR update.
Stock lagged S&P 500's 12.0% gain with only 1.06% YTD return.
Premium P/E of 51.54 may limit multiple expansion per Canaccord.
Investors calibrate long-term Medicare impact on hospital reimbursement levels.
Edwards Lifesciences has received FDA approval for the Triformis Resilia, marking the first surgical valve specifically designed and approved for the tricuspid position. Approved in May 2026, the device addresses a long-standing unmet need where surgeons previously had to use mitral valves for tricuspid replacements...
Bullish Signals
FDA approved May 2026 for first dedicated tricuspid surgical valve.
Addresses unmet need replacing mitral valves for tricuspid replacements.
No conduction abnormalities or AV node disruption in pre-clinical studies.
Integrity Preservation tech enhances durability and hemodynamic performance.
Launch planned second half 2026 expanding Resilia portfolio.
Edwards Lifesciences has released long-term durability data from the COMMENCE aortic trial, focusing specifically on its RESILIA tissue technology. Announced at the 106th American Association for Thoracic Surgery Annual Meeting in Singapore, these findings highlight the performance of Edwards' surgical valves after a decade of...
Bullish Signals
97.9% freedom from structural deterioration at 10 years.
98.6% freedom from non-structural dysfunction sustained over time.
Over 500,000 patients treated worldwide with RESILIA valves.
30,000 procedures completed in the Asia-Pacific region.
Supports durable valve need for younger Asian patients.
Edwards Lifesciences Corporation reported its financial results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company generated sales of USD 1,715.5 million, representing an increase from USD 1,553.1 million in the same period last year. Net income...
Bullish Signals
Revenue grew 14% to USD 1,715.5 million.
Net income rose to USD 307.5 million.
EPS improved to USD 0.53.
Bearish Signals
Net income declined to USD 930.1M vs USD 982.3M prior-year.
EPS decreased to USD 1.61 from USD 1.70 last year.
Edwards Lifesciences (NYSE:EW) presented new clinical data demonstrating significant patient benefits from its PASCAL and TAVR programs. The CLASP IITR trial for the PASCAL transcatheter edge-to-edge repair system met its six-month primary endpoint, showing treated patients were nearly twice as likely to experience a composite...
Bullish Signals
PASCAL system met endpoint; treated patients twice as likely to benefit.
Edwards Lifesciences Corp (NYSE: EW) shares rallied 4.05% in morning trading following the release of third-quarter earnings that beat analyst estimates by $0.09 per share and $17.21 million in revenue. The company reported EPS of $1.07 on revenues of $615.5 million, exceeding expectations for both...
Bullish Signals
EPS beat estimates by $0.09 at $1.07.
Revenue exceeded expectations by $17.21 million.
Shares rallied 4.05% on strong earnings.
Forward guidance expects EPS of $1.11-$1.21.
Stock gained 20.64% year-to-date.
Bearish Signals
Q4 revenue guidance of $620M-$660M trails analyst consensus of $630.68M.
Edwards Lifesciences Corporation reported strong financial results for the quarter ended July 23, 2026, with shares closing at $88.22 on September 18, 2026. The company beat analyst expectations significantly, posting earnings per share of $0.78 compared to a consensus of $0.74 and generating revenue of...
Edwards Lifesciences Corporation (NYSE: EW) reported strong quarterly financial results, posting earnings per share (EPS) of $0.78, which beat the analyst consensus of $0.74. Revenue increased by 13.6% year over year to reach $1.74 billion, exceeding expectations of $1.70 billion. The company maintains a robust...
Bullish Signals
EPS beat estimates at $0.78 vs $0.74.
Revenue grew 13.6% YoY to $1.74 billion.
Raised Q3 and full-year 2026 EPS guidance.
Institutional ownership stands high at 79.46%.
Bearish Signals
Azimuth Capital sold 22,092 shares, dropping holdings by 9.9%.
Insiders Lippis and Dahl reduced positions via pre-arranged plans.
Edwards Lifesciences Corporation (NYSE: EW) reported stronger-than-expected quarterly results, posting $0.78 in earnings per share and $1.74 billion in revenue, representing a 13.6% year-over-year increase. The company's stock opened at $90.00, trading near the middle of its 12-month range, with analysts maintaining a 'Moderate Buy'...
Bullish Signals
EPS hit $0.78, revenue reached $1.74B, both beating estimates.
Bearish Signals
B. Metzler reduced stake by 25.5%, selling 14,264 shares.
Insiders sold 5,045 shares worth $457,749 in 90 days.
Edwards Lifesciences Corporation (NYSE: EW) reported strong quarterly financial results, exceeding analyst expectations with earnings per share of $0.78 against a consensus of $0.74 and revenue of $1.74 billion, representing a 13.6% year-over-year increase. The company demonstrated robust profitability with a net margin of 15.43%...
Bullish Signals
EPS beat at $0.78 vs $0.74 consensus.
Revenue up 13.6% YoY to $1.74 billion.
Nykredit invested $20.64M, boosting confidence.
Debt-to-equity ratio is a strong 0.06.
Analysts upgraded targets to $110.00.
Bearish Signals
Insiders sold 5,045 shares worth $457,749 in 90 days.
Stock traded near $89.89 below $100.27 analyst target.
Diversified Trust Co significantly reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 45.7% during the first quarter, selling 16,910 shares to hold a remaining stake of 20,057 shares valued at $1.6 million. While Diversified Trust exited substantially, several other institutional investors including JPL Wealth...
Bullish Signals
EPS beat: $0.78 vs $0.73 consensus.
Revenue grew 16.7% to $1.65 billion.
FY 2026 EPS guidance: $2.95-$3.05.
Current ratio of 4.42 and debt-to-equity of 0.06.
Institutional inflows from JPL Wealth and MV Capital.
Bearish Signals
Diversified Trust Co reduced position by 45.7% in Q1.
VP Bobo sold $2M; CFO Ullem sold $1M recently.
Total insider selling hit $6.7M over last 90 days.
Wall Street analysts project Edwards Lifesciences (EW) to report quarterly earnings of $0.73 per share, marking a 9% year-over-year increase. Revenue is estimated at $1.68 billion, representing an 8% rise from the prior-year quarter. Over the past 30 days, the consensus EPS estimate has been...
Edwards Lifesciences (NYSE: EW) announced that the U.S. Food and Drug Administration has approved its PASCAL Precision device for a new indication in severe symptomatic tricuspid regurgitation. This approval covers patients with leakage who have not responded to optimal medical therapy and are at intermediate...
Bullish Signals
FDA approved PASCAL for severe tricuspid regurgitation.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)